Skip to main content

Table 3 Expected number of epoetin SEB users in Canada, years 1 to 5

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

 

Year 1

Year 2

Year 3

Year 4

Year 5

Number of SEB users

982

4,393

8,344

13,785

17,826

  1. SEB = subsequent entry biologic.
Back to article page

Canadian Journal of Kidney Health and Disease

ISSN: 2054-3581

Contact us